tuneTypical Dose
2-5 g/day
Supplement
D-Ribose
D-Ribose
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
early to short-term
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
D-ribose is a pentose sugar used to support ATP repletion in select energy-depleted clinical settings, though evidence is preliminary and not nootropic.
The human literature on D-ribose is small and mostly exploratory. An uncontrolled pilot in fibromyalgia and chronic fatigue syndrome and a tiny cardiac pilot both suggest possible symptomatic benefit, but neither provides strong confirmatory evidence. Claims for general energy, athletic performance, or cognition remain weak, and glucose-related tolerability still matters.
Glycolytic and ATP-support rationale with limited high-quality nootropic translation.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Subjective fatigue reduction in select contexts
- Potential short-term endurance support
Secondary Outcomes
- GI tolerance burden
- No clear nootropic enhancement signal
Safety
Contraindications and Interactions
Contraindications
- Unstable diabetes
- Severe renal dysfunction
Side effects
- Bloating/diarrhea
- Mild headaches
- Possible glucose swing symptoms
Interactions
- Antidiabetic therapies
- Metabolic stimulants
Avoid if
- Active hypoglycemia risk
- Poor glucose control
Evidence
Study-level References
d-ribose-SRC-001Open-label uncontrolled pilot study
Sourceopen_in_newTeitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006;12(9):857-862. doi:10.1089/acm.2006.12.857. PMID:17109576.
Population: Adults with chronic fatigue syndrome and/or fibromyalgia.
Dose protocol: 5 g three times daily in an open-label pilot
Key findings: Reported broad symptom improvement in fibromyalgia and chronic fatigue syndrome.
Notes: Uncontrolled design. High placebo-response and expectation bias risk.
Paper content
The study reported broad symptom improvement, but because it was open-label and uncontrolled, it should be treated as hypothesis-generating rather than confirmatory evidence for D-ribose.
d-ribose-SRC-002Pilot clinical study
Sourceopen_in_newBayram M, St Cyr JA, Abraham WT. D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. Ther Adv Cardiovasc Dis. 2015;9(3):56-65. doi:10.1177/1753944715572752. PMID:25701016.
Population: Eleven patients with heart failure symptoms, preserved systolic function, and diastolic dysfunction.
Dose protocol: Pilot D-ribose supplementation in diastolic dysfunction / HFpEF-like patients
Key findings: Small pilot suggested possible diastolic-function and quality-of-life improvement in a cardiac population.
Notes: Mechanistically relevant but not transferable to general energy or nootropic use.
Paper content
This small pilot provides only preliminary support for D-ribose in an energy-depleted cardiac population. It is relevant for mechanistic plausibility, not for broad fatigue or performance claims.